ATC Group: N07AA Anticholinesterases

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N07AA in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N07 Other nervous system drugs
3 N07A Parasympathomimetics
4 N07AA Anticholinesterases

Group N07AA contents

Code Title
N07AA01 Neostigmine
N07AA02 Pyridostigmine
N07AA03 Distigmine
N07AA30 Ambenonium
N07AA51 Neostigmine, combinations

Active ingredients in N07AA

Active Ingredient Description

Ambenonium (as ambenonium dichloride) is a cholinesterase inhibitor used in the management of myasthenia gravis. Ambenonium exerts its actions against myasthenia gravis by competitive reversible inhibition of acetylcholinesterase, the enzyme responsible for the hydrolysis of acetylcholine.


Neostigmine inhibits cholinesterase activity and prolongs and intensifies the muscarinic and nicotinic effects of acetylcholine. The anticholinesterase actions of neostigmine are reversible. It is used mainly for its action on skeletal muscle and less frequently to increase the activity of smooth muscle.


Pyridostigmine is an antagonist to cholinesterase, the enzyme which normally destroys acetylcholine. The action of pyridostigmine can briefly be described, therefore, as the potentiation of naturally occurring acetylcholine.

Related product monographs

Title Information Source Document Type  
MESTINON Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
NEOSTIGMINE Sterile injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
UBRETID Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC